Clario delivers the leading endpoint technology solutions for clinical trials. Through experience gained from over 19,000 clinical trials delivered in support of 870 regulatory approvals, Clario fuses scientific expertise and global scale into the broadest endpoint technology platform to enable pharmaceutical, biotech and medical device partners to transform lives.

Through Trial Anywhere™, Clario has mastered the ability to generate rich evidence across all trial models: decentralized, hybrid and site-based clinical trials. With 30 facilities in nine countries across North America, Europe and Asia Pacific, Clario’s global team of science, technology and operational experts has been delivering the richest clinical evidence for nearly 50 years.

In early 2021, ERT merged with Bioclinica, a technological and scientific leader in clinical imaging. This combination creates a global leader in clinical trial endpoint technology and a leading partner to pharmaceutical and biotechnology companies, providing best-in-class technology, scientific and therapeutic expertise, and digital innovation with a strong focus on customer service. In November 2021, the combined company was renamed Clario.

Nordic Capital Fund VIII acquired ERT in 2016. In 2020, Nordic Capital re-invested alongside Astorg and Novo through Fund IX. Nordic Capital’s ownership focus is to invest in the continued development of the business with the aim of further expanding operational capabilities and selectively pursuing add-on investments to support future growth.


Sector Icon


Sector Icon

Tech & Payments

Key Information

Revenues Icon

Revenues 2021

EUR 780 million

Employees Icon



Ownership Icon


Nordic Capital Fund IX, co-controlling shareholding

Head Office Icon

Head office

Philadelphia, Pennsylvania, USA

Investment Icon

Investment date